This is a prospective cohort study to screen for TmAg in symptomatic hospitalized patients (Cohort 1) and symptomatic or asymptomatic outpatients (Cohort 2) with advanced HIV disease, using the Mp1p EIA, and to determine their diagnostic and prognostic values and the impact on patient outcomes through close follow up over six to twelve months.